Pancreatic cancer currently has the lowest overall survival rate across all major cancers. The majority of pancreatic cancer patients overall live 8 to 12 months after diagnosis, and the instances of the disease are on the rise.
Drs. Olive and Eberle-Singh and their collaborators tested PTC596, an experimental compound, in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy. The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Dr. Olive says. “Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer." Read the full article at CUIMC Newsroom.
Dr. Olive is a pancreatic cancer researcher at the Herbert Irving Comprensive Cancer Center (HICCC) and associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons. This study was led by Dr. Eberle-Singh, while she was a graduate student at Columbia.